AAV cis -regulatory sequences are correlated with ocular toxicity
Top Cited Papers
Open Access
- 4 March 2019
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 116 (12), 5785-5794
- https://doi.org/10.1073/pnas.1821000116
Abstract
Adeno-associated viral vectors (AAVs) have become popular for gene therapy, given their many advantages, including their reduced inflammatory profile compared with that of other viruses. However, even in areas of immune privilege such as the eye, AAV vectors are capable of eliciting host-cell responses. To investigate the effects of such responses on several ocular cell types, we tested multiple AAV genome structures and capsid types using subretinal injections in mice. Assays of morphology, inflammation, and physiology were performed. Pathological effects on photoreceptors and the retinal pigment epithelium (RPE) were observed. Müller glia and microglia were activated, and the proinflammatory cytokines TNF-α and IL-1β were up-regulated. There was a strong correlation between cis-regulatory sequences and toxicity. AAVs with any one of three broadly active promoters, or an RPE-specific promoter, were toxic, while AAVs with four different photoreceptor-specific promoters were not toxic at the highest doses tested. There was little correlation between toxicity and transgene, capsid type, preparation method, or cellular contaminants within a preparation. The toxic effect was dose-dependent, with the RPE being more sensitive than photoreceptors. Our results suggest that ocular AAV toxicity is associated with certain AAV cis-regulatory sequences and/or their activity and that retinal damage occurs due to responses by the RPE and/or microglia. By applying multiple, sensitive assays of toxicity, AAV vectors can be designed so that they can be used safely at high dose, potentially providing greater therapeutic efficacy.Keywords
Funding Information
- Howard Hughes Medical Institute (NA)
- Astellas Pharma (NA)
- City University of Hong Kong (9610345)
- Research Grants Council, University Grants Committee (21105916)
- National Natural Science Foundation of China (81770937)
- HHS | NIH | National Eye Institute (K08-EY023993-05)
- Massachusetts Lions Eye Research Fund, Iraty Award (NA)
- HHS | NIH | National Eye Institute (U01 EY025497)
- Howard Hughes medical Institute Medical Student Fellowship (NA)
This publication has 94 references indexed in Scilit:
- Self-complementary AAVs Induce More Potent Transgene Product-specific Immune Responses Compared to a Single-stranded GenomeMolecular Therapy, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus ManufacturingHuman Gene Therapy, 2010
- Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everythingJournal of Internal Medicine, 2010
- Development and diversification of retinal amacrine interneurons at single cell resolutionProceedings of the National Academy of Sciences of the United States of America, 2009
- Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences of the United States of America, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008